Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Akeso Huike (Shanghai) Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, JOHANSEN, PETER N., who is also identified as the busiest examiner for this portfolio. The prosecution is situated within 1 distinct art unit. This individual is responsible for 1 busiest examiner pending action at the office.
For a practitioner, this data indicates a centralized prosecution effort. With only 1 distinct examiner and 1 distinct art unit involved, there is no variance in examiner behavior or art unit trends to navigate across the portfolio. The current engagement with the patent office in the Biotechnology & Pharmaceuticals space is focused on the reported activity for this specific filing. The role of the busiest examiner with 1 busiest examiner pending action confirms that all legal strategy is directed through JOHANSEN, PETER N. at the USPTO. This allows for a streamlined approach without the complexity of managing multiple examiner relationships or disparate art unit requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18696546 | ANTI-LAG3 BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE | JOHANSEN, PETER N. | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18696546 | ANTI-LAG3 BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE | JOHANSEN, PETER N. | 1644 | §102§112DP | Non-Final OA | — | Pending | Mar 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAkeso Huike (Shanghai) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Peter N. Johansen has the most, with 1 of Akeso Huike (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
